NKGen Biotech Inc NKGN
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.20
- Bid/Ask
- $0.20 / $0.40
- Shares Outstanding
- 130.60M
- Market Cap
- $326,505.58
- Volume/Avg
- 14,516 / 9,593
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 26
- Website
- https://www.nkgenbiotech.com
Valuation
|
Metric
|
NKGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NKGN
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.05 |
Interest Coverage | −9.86 |
Quick Ratio
NKGN
Profitability
|
Metric
|
NKGN
|
|---|---|
Return on Assets (Normalized) | −144.26% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NKGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|m<&^<<# | LOCK|>q@DD | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&Z&ghv! | LOCK|l$?n | $84B | |||
| Moderna Inc
MRNA
| LOCK|<NRXz?> | LOCK|f& | $81B | |||
| argenx SE ADR
ARGX
| LOCK|$>L&D!m | LOCK|$rk | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|fyG%!# | LOCK|>yN | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>%JJs#P | LOCK|^cdY | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&$<tw$M | LOCK|$<NJ^ | $28B | |||
| Incyte Corp
INCY
| LOCK|@&W>zFm | LOCK|mCS | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|v$Vk>x | LOCK|m< | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|KGDL%^ | LOCK|f$C | $14B |
United States